Dr. Robert M. Jotte, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Vanderbilt University School of Medicine (1996)
- Years since graduation
- 30
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 797
Licensed in Colorado since 1998, according to the Colorado Department of Regulatory Agencies. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1996Medical school: Vanderbilt University School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
CO license DR.0036770 (first issued 1998; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Adventhealth PArker Parker, CO
- Hca-Healthone DBA Swedish Medical Center Englewood, CO
- Adventhealth Castle Rock Castle Rock, CO
- Sky Ridge Medical Center Lone Tree, CO
- HCA Healthone Rose Denver, CO
Medical groups
- Rocky Mountain Cancer Centers LLP (132 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 797
- Services billed
- 82,295
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, fosaprepitant, 1 mg | 9,300 | 21 |
| Injection, denosumab, 1 mg | 3,840 | 19 |
| Injection, dexamethasone sodium phosphate, 1 mg | 2,160 | 45 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 2,053 | 490 |
| Blood test, comprehensive group of blood chemicals | 1,745 | 462 |
| Insertion of needle into vein for collection of blood sample | 1,491 | 471 |
| Injection, granisetron hydrochloride, 100 mcg | 970 | 22 |
| Injection, palonosetron hcl, 25 mcg | 830 | 32 |
| Gammaglobulin (immune system protein) measurement | 797 | 75 |
| Established patient office or other outpatient visit, 30-39 minutes | 691 | 366 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Xarelto (rivaroxaban) Other prescribers in Lone Tree, CO | 146 |
| Eliquis (apixaban) Other prescribers in Lone Tree, CO | 146 |
| Acyclovir Other prescribers in Lone Tree, CO | 108 |
| Warfarin Sodium Other prescribers in Lone Tree, CO | 96 |
| Enoxaparin Sodium Other prescribers in Lone Tree, CO | 74 |
| Levothyroxine Sodium Other prescribers in Lone Tree, CO | 72 |
| Prochlorperazine Maleate Other prescribers in Lone Tree, CO | 68 |
| Dexamethasone Other prescribers in Lone Tree, CO | 66 |
| Lenalidomide | 62 |
| Ondansetron Hcl Other prescribers in Lone Tree, CO | 54 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 5 payments worth $3,874 in total to this clinician.
| Takeda Pharmaceuticals U.S.A., Inc. | $1,908 |
|---|---|
| AbbVie Inc. | $1,809 |
| Ethicon Inc. | $134 |
| Iovance Biotherapeutics, Inc. | $24.22 |
| Consulting Fee | $3,708 |
|---|---|
| Food and Beverage | $167 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. Mar 18, 2025 | Consulting Fee ALUNBRIG · ONCOLOGY | $1,908 |
| AbbVie Inc. Dec 18, 2025 | Consulting Fee | $1,800 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 41 industry-funded studies in 2025, from 16 companies. The companies reported $1,639,692 in research payments for these studies, mostly to the institutions running them.
- A randomized phase 3 openlabel study to evaluate SGNB6A compared with docetaxel in adult subjects with previously treated nonsmall cell lung cancer
Pfizer Inc. - ALI-4201
Puma Biotechnology, Inc. - A phase III,two arm,parallel,randomized,multi center,open label,global study to determine the efficacy of volrustomig,plus chemotherapy versus pembrolizumab plus chemotherapy for first line treatment of patients with …
AstraZeneca Pharmaceuticals LP - A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma
Beone Medicines Ltd. · Completed · NCT05909904 - Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Mirati Therapeutics, Inc. · Recruiting · NCT04613596 - A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy f…
AstraZeneca Pharmaceuticals LP - Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
Mirati Therapeutics, Inc. · Active, not recruiting · NCT05609578 - A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Mas…
Amgen Inc. - A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors
Incyte Corporation - A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line T…
Janssen Research & Development, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.